Medical News Today (Free subscription) | 25/11/2008
Cepheid (Nasdaq: CPHD) announced that Health Canada has issued a medical device license for its Xpert(TM) MRSA/SA Skin and Soft Tissue (SSTI) test for the rapid detection of Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA, typically Methicillin-sensitive) in skin and soft tissue infections.
PR News Wire (Free subscription) | 24/11/2008
The GeneXpert(R) System is a closed, self-contained, fully-integrated and automated platform that represents a paradigm shift in the automation of molecular analysis, producing accurate results in a timely manner with minimal risk of contamination. The GeneXpert System is the only system to combine on- board sample preparation with real-time PCR (polymerase chain reaction) amplification and detection...
Business Wire (Free subscription) | 11/11/2008
CHICAGO--(BUSINESS WIRE)--Zacks.com releases the latest Analyst Interview. Today’s interview is with senior analyst Tom Park, who discusses Cepheid Inc.
PR News Wire (Free subscription) | 10/11/2008
Test Simultaneously Identifies and Differentiates More Virulent 027 Strain from Common Strains SUNNYVALE, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced the release of Xpert(TM) C. difficile as a European CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. For the first time, European hospitals will have access to a reliable,...
Medical News Today (Free subscription) | 05/11/2008
Cepheid (Nasdaq: CPHD) announced the U.S. Food & Drug Administration (FDA) categorized Cepheid's Xpert(TM) MRSA/SA Blood Culture (BC) test as "Moderate Complexity" under the Clinical Laboratory Improvement Amendments (CLIA). The new test is designed for on-demand detection of Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA), (typically Methicillin-sensitive)...
Red Orbit (Free subscription) | 04/11/2008
SUNNYVALE, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Cepheid today announced the U.S. Food & Drug Administration (FDA) categorized Cepheid's Xpert(TM) MRSA/SA Blood Culture (BC) test as "Moderate Complexity" under the Clinical Laboratory Improvement Amendments (CLIA).
PR News Wire (Free subscription) | 03/11/2008
SUNNYVALE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that it has entered into a definitive agreement to acquire Stretton Scientific Limited, a privately held distributor of scientific diagnostic, measuring and monitoring equipment based in Stretton, England. Stretton Scientific currently distributes Cepheid's SmartCycler(R) System, among other diagnostic...
Seeking Alpha China (Free subscription) | 29/10/2008
Cepheid (CPHD) Q3 2008 Earnings Call Complete Story »
Medical News Today (Free subscription) | 28/10/2008
Cepheid (Nasdaq: CPHD) noted an announcement from Birmingham Children's Hospital highlighting results using Cepheid's Xpert(TM) MRSA test, which runs on the GeneXpert(R) System, to implement a screening program for all patients being admitted to its Intensive Care Unit (ICU).
PR News Wire (Free subscription) | 28/10/2008
GeneXpert(R) System Momentum Drives 71% Year-Over-Year Growth in Core Clinical Business SUNNYVALE, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today reported revenue for the third quarter of 2008 of $44.9 million, an increase of 24% over the third quarter of fiscal 2007. Net loss was $6.5 million, or $(0.11) per share, which compares to revenue of $36.3 million and a...
PR News Wire (Free subscription) | 27/10/2008
SUNNYVALE, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today noted an announcement from Birmingham Children's Hospital highlighting results using Cepheid's Xpert(TM) MRSA test, which runs on the GeneXpert(R) System, to implement a screening program for all patients being admitted to its Intensive Care Unit (ICU). The Birmingham Children's Hospital announcement,...
Rashid's Blog (Free subscription) | 30/11/2008
Variable stars are stars that vary in brightness over time. In most cases, these changes occur very slowly over a period of months or even years. In some cases, however, the changes take place in a matter of hours. The category variable stars encompasses several different types of stars that vary in brightness for entirely different reasons. Examples include red giants, eclipsing binaries, Cepheid...
Global Financial News (Free subscription) | 20/11/2008
... DCM ) was downgraded at Citigroup to Hold from Buy. Analyst initiations: Needham expects shares of Cepheid (NASDAQ: CPHD ) to be driven by continued market penetration in the hospital acquired infection market, new test introductions, GeneXpert Infinity sales, and molecular diagnostics growth from sales outside of traditional molecular testing areas. Shares were initiated with a Buy rating...
Business Wire (Free subscription) | 20/11/2008
NEW YORK--(BUSINESS WIRE)--Reportlinker.com announces that a new market research report related to the Biotechnologies and Genetics industry is available in its catalogue. World Molecular Diagnostics Market
PR News Wire (Free subscription) | 04/11/2008
Dorset County Hospital screens elective and Orthopaedic admissions patients in only 75 minutes using Cepheid's advanced Xpert(TM) MRSA technology DORSET, England, Nov. 4 /PRNewswire/ -- Dorset County Hospital (DCH) is working hard to reduce MRSA infections and, as part of that plan, has introduced enhanced MRSA surveillance. As part of the programme, DCH is screening all elective and orthopaedic...
